Price movement over the last 24 hours
ACADIA Pharmaceuticals Inc. vs L3Harris Technologies Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while L3Harris Technologies Inc trades at $292 (market cap $55.03B). The key difference: L3Harris Technologies Inc is far larger — about 12.3× ACADIA Pharmaceuticals Inc.'s market cap, and L3Harris Technologies Inc pays a 1.69% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | LHX | |
|---|---|---|
Market Cap | $4.49B | $55.03B |
Sector | Health | Industrials |
52-Week High | $28.06 | $378.48 |
52-Week Low | $20.06 | $257.09 |
Enterprise Value | $3.69B | $65.80B |
Dividend Yield | — | 1.69% |
Trailing returns across standard periods
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →